摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-pyrrolidyl-1,1-dimethoxyethane | 339199-74-5

中文名称
——
中文别名
——
英文名称
1-pyrrolidyl-1,1-dimethoxyethane
英文别名
1-(1,1-Dimethoxyethyl)pyrrolidine
1-pyrrolidyl-1,1-dimethoxyethane化学式
CAS
339199-74-5
化学式
C8H17NO2
mdl
——
分子量
159.228
InChiKey
NSJQTBSPDZYLQG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    170.4±30.0 °C(Predicted)
  • 密度:
    1.003±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-pyrrolidyl-1,1-dimethoxyethane5’-脱氧-5-氟胞嘧啶核苷甲醇 为溶剂, 反应 10.0h, 以15%的产率得到1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-4-((1-(pyrrolidin-1-yl)ethylidene)amino)pyrimidin-2(1H)-one
    参考文献:
    名称:
    Design, synthesis and anti-tumoractivity of novel amidine derivatives of doxifluridine
    摘要:
    A series of novel amidine derivatives of doxifluridine were synthesized using acid amide as the starting material, and their antitumor activity was evaluated in A549 cells. Compounds 10 and 11 demonstrated were more potent than 5-Fu, which was used as a positive control. Compound 10, which were found to be the most potent one with IC50 of 3.2 mu mol/L, was 16 times more potent than 5-Fu with IC50 of 52 mu mol/L to the A549 cells. A new route was designed to synthesize 5'-deoxy-5-fluorocytidine. All compounds were characterized by H-1 NMR, MS and X-ray spectras in detail. (C) 2009 K. Li. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
    DOI:
    10.1016/j.cclet.2009.10.013
  • 作为产物:
    描述:
    1-乙酰基吡咯烷sodium methylate硫酸二甲酯 以 Petroleum ether 为溶剂, 反应 4.5h, 生成 1-pyrrolidyl-1,1-dimethoxyethane
    参考文献:
    名称:
    Design, synthesis and anti-tumoractivity of novel amidine derivatives of doxifluridine
    摘要:
    A series of novel amidine derivatives of doxifluridine were synthesized using acid amide as the starting material, and their antitumor activity was evaluated in A549 cells. Compounds 10 and 11 demonstrated were more potent than 5-Fu, which was used as a positive control. Compound 10, which were found to be the most potent one with IC50 of 3.2 mu mol/L, was 16 times more potent than 5-Fu with IC50 of 52 mu mol/L to the A549 cells. A new route was designed to synthesize 5'-deoxy-5-fluorocytidine. All compounds were characterized by H-1 NMR, MS and X-ray spectras in detail. (C) 2009 K. Li. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
    DOI:
    10.1016/j.cclet.2009.10.013
点击查看最新优质反应信息

文献信息

  • [EN] PROCESS FOR THE SYNTHESIS OF 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN 'B ! FURAN-2-ONE<br/>[FR] PROCEDE DE SYNTHESE DE 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN [B] FURAN-2-ONE
    申请人:UPJOHN CO
    公开号:WO2004056749A1
    公开(公告)日:2004-07-08
    The present invention relates to a process for the synthesis of 3,3a,6,6a-tetrahydo-2H-cyclopentan[b]furan-2-one.
    本发明涉及一种合成3,3a,6,6a-四氢-2H-环戊基呋喃-2-酮的方法。
  • Process for preparing adjacently disubstituted ketones, novel prostaglandins E1 and anti-thrombotic compositions containing them
    申请人:TEIJIN LIMITED
    公开号:EP0019475A2
    公开(公告)日:1980-11-26
    Novel 7-hydroxyprostaglandins E1, or stereoisomers thereof, or protected derivatives thereof, having the following formula: wherein R3 represents H, CH3 or C2H5, R9 represents H or CH3, R10 and R are identical or different, and each represents H, tetrahydropyranyl or t-butyldimethylsilyl. Also provided is a process for producing adjacently disubstituted ketones including the above novel compounds, which process comprises reacting an a, #-unsaturated carbonyl compound with a cuprous salt and an organolithium compound in an aprotic inert organic medium in the presence of trialkylphosphine, the amounts of said cuprous salt and said organolithium compound being substantially equimolar, and reacting the product with a protected acetal derivative of an organic carbonyl compound or an aldehyde in the presence of a Lewis acid if necessary followed by reacting the product with a proton donor.
    具有下式的新型 7-羟基前列腺素 E1 或其立体异构体或其保护衍生物: 其中 R3 代表 H、CH3C2H5,R9 代表 H 或 ,R10 和 R 相同或不同,且各自代表 H、四氢吡喃基或叔丁基二甲基基。 还提供了一种生产包括上述新型化合物在内的邻接二取代酮的工艺,该工艺包括在三 烷基膦存在下,在惰性有机介质中使 a,#-不饱和羰基化合物与亚盐和有机锂化合物 反应、所述亚盐和所述有机锂化合物的量基本等摩尔,必要时在路易斯酸存在下,使产物与有机羰基化合物或醛的受保护缩醛生物反应,然后使产物与质子供体反应。
  • Process for the synthesis of 3.3A.6.6A-tetrahydro-2H-cyclopentan[b]furan-2-one
    申请人:——
    公开号:US20040147775A1
    公开(公告)日:2004-07-29
    The present invention relates to a process for the synthesis of 3,3a,6,6a-tetrahydo-2H-cyclopentan[b]furan-2-one.
    本发明涉及一种合成 3,3a,6,6a-四氢-2H-环戊烷[b]呋喃-2-酮的工艺。
  • PROCESS FOR THE SYNTHESIS OF 3,3A,6,6A-TETRAHYDRO-2H-CYCLOPENTAN[B]FURAN-2-ONE
    申请人:Pharmacia & Upjohn Company LLC
    公开号:EP1581479A1
    公开(公告)日:2005-10-05
  • US4315032A
    申请人:——
    公开号:US4315032A
    公开(公告)日:1982-02-09
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)